MedTrace Logo

Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.

NCT07289035 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-12-17

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of TMX in adults patients with cystic fibrosis who do not have mutations currently eligible for therapy with modulator drugs.

The main questions it aims to answer is:

. What medical problems do participants have when taking drug TMX?

Participants will:

* Take drug TMX every day for 6 months
* Visit the clinic once every 28 days for checkups and tests

Conditions

  • Cystic Fibrosis - Complete

Interventions

DRUG

Tamoxifen Citrate 20Mg Tab

One tablet per day (20 mg/day), in the morning.

Sponsors & Collaborators

  • Azienda Ospedaliera Universitaria Integrata Verona

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-15
Primary Completion
2026-04-01
Completion
2027-02-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07289035 on ClinicalTrials.gov